Head-To-Head Review: Lifecore Biomedical (NASDAQ:LFCR) and Otsuka (OTCMKTS:OTSKY)

Lifecore Biomedical (NASDAQ:LFCR) and Otsuka (OTCMKTS:OTSKY) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Earnings & Valuation

This table compares Lifecore Biomedical and Otsuka”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87 million	1.23	-$40.50 million	($1.07)	-3.93
Otsuka	$16.51 billion	2.30	$2.43 billion	$2.49	14.20

Otsuka has higher revenue and earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Otsuka, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lifecore Biomedical and Otsuka’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Otsuka	15.50%	12.86%	9.59%

Analyst Ratings

This is a summary of current recommendations and price targets for Lifecore Biomedical and Otsuka, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1	1	1	0	2.00
Otsuka	1	2	1	0	2.00

Lifecore Biomedical presently has a consensus price target of $6.50, suggesting a potential upside of 54.76%. Given Lifecore Biomedical’s higher probable upside, analysts clearly believe Lifecore Biomedical is more favorable than Otsuka.

Insider and Institutional Ownership

83.4% of Lifecore Biomedical shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Lifecore Biomedical has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Otsuka has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500.

Summary

Otsuka beats Lifecore Biomedical on 8 of the 12 factors compared between the two stocks.

About Lifecore Biomedical

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

About Otsuka

Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement instruments, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, and insecticide and toiletry products. In addition, the company offers IT solution services; adhesive tapes; flaky titanate and compounds; IV solutions; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; urinary tract health products; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. Otsuka Holdings Co., Ltd. was founded in 1921 and is headquartered in Tokyo, Japan.